Physician profile
Michael Lee Smith
NPI 1760782973
$2,360.71
in general payments reported to CMS, 2019-2025
25 companies · $530 in 2025
The $530 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $555 · 2020: $266 · 2021: $173 · 2022: $305 · 2023: $256 · 2024: $277 · 2025: $530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,062.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,062.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $393.72 | 2019-2024 | Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $297.06 | 2019-2025 | Jardiance |
| Amgen INC. | $272.93 | 2019-2025 | Repatha, Evenity, Prolia |
| Lilly USA, LLC | $228.50 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Edwards Lifesciences Corporation | $187.03 | 2025 | Sapien 3 Ultra Resilia |
| Novo Nordisk INC | $159.41 | 2019-2024 | Rybelsus, Ozempic |
| Abbott Laboratories | $122.83 | 2021-2025 | Freestyle Libre 3 |
| Boston Scientific Corporation | $111.11 | 2023-2024 | Watchman Flx |
| Sanofi-Aventis U.S. LLC | $80.13 | 2019-2025 | |
| Glaxosmithkline, LLC. | $66.63 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $61.83 | 2019-2024 | Spravato |
| Allergan, INC. | $58.76 | 2019-2020 | |
| Astellas Pharma US INC | $52.24 | 2021-2025 | Veozah |
| Amarin Pharma, INC. | $40.47 | 2019 | |
| Exact Sciences Corporation | $40.16 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $33.78 | 2020 | |
| Daiichi Sankyo INC. | $27.05 | 2019-2020 | |
| Nevro Corp. | $21.83 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $18.80 | 2019 | |
| Abbvie INC. | $17.54 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.97 | 2023 | Relistor |
| Therapeuticsmd, INC. | $15.77 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.19 | 2019 | |
| Merck Sharp & Dohme LLC | $11.92 | 2019 | |
| Pfizer INC. | $11.05 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.